A 52-year-old woman with chronic hepatitis B (HBsAg+, HBeAg−, anti-HBe+) and cirrhosis is found to have a 15 mm nodule in the liver on ultrasound. AFP is 85 ng/mL. Which investigation is most appropriate for confirming the diagnosis of hepatocellular carcinoma?

## Diagnosis of HCC in Nodules 10–20 mm **Key Point:** For nodules 10–20 mm in cirrhotic patients, AASLD guidelines require **two imaging modalities** showing typical HCC features (arterial phase enhancement + washout) **OR** one imaging modality with AFP > 400 ng/mL. In this case, with AFP 85 ng/mL, **two imaging studies are mandatory**. ### Diagnostic Algorithm for 10–20 mm Nodules ```mermaid flowchart TD A[Nodule 10-20 mm detected]:::outcome --> B{AFP level?}:::decision B -->|AFP > 400 ng/mL| C[One imaging modality with APHE + washout = HCC]:::action B -->|AFP < 400 ng/mL| D[Require TWO imaging modalities with APHE + washout]:::action C --> E[HCC diagnosed]:::outcome D --> F[CT + MRI both showing typical pattern]:::action F --> E D --> G[One imaging study atypical]:::decision G --> H[Biopsy or follow-up imaging at 3-4 months]:::action ``` ### Why MRI as the Second Modality? | Feature | CT | MRI | |---|---|---| | **Arterial phase enhancement detection** | Excellent | Excellent | | **Washout pattern visibility** | Good | Excellent (especially on hepatobiliary agents) | | **Sensitivity for small HCC** | 70–80% | 80–90% | | **Specificity** | > 95% | > 95% | | **Advantage in cirrhosis** | Standard | Superior for lesion characterization; hepatobiliary contrast agents (gadoxetate) improve specificity | | **Radiation exposure** | Yes | No | **High-Yield:** When two imaging modalities are needed, **CT + MRI** is the standard combination. MRI with hepatobiliary contrast agents (gadoxetate disodium, gadobenate dimeglumine) provides superior characterization of washout and can detect arterial phase hyperenhancement (APHE) more reliably than CT in cirrhotic livers. **Clinical Pearl:** Hepatobiliary contrast agents are taken up by functioning hepatocytes. HCC cells have reduced uptake, leading to **hypointensity in the hepatobiliary phase** — an additional diagnostic criterion that increases specificity for HCC diagnosis. ### Why Not the Other Options? - **CT alone:** While CT is excellent, guidelines require **two modalities** when AFP < 400 ng/mL. CT alone is insufficient for nodules 10–20 mm with low AFP. - **Biopsy:** Invasive and unnecessary when imaging criteria can be met. Reserved for discordant imaging or when diagnosis remains uncertain after two imaging studies. - **AFP level > 200 ng/mL:** AFP is a biomarker, not an imaging investigation. Serum AFP alone cannot diagnose HCC; it must be combined with imaging. AFP > 400 ng/mL allows diagnosis with **one imaging modality**, but this patient's AFP is 85 ng/mL. **Warning:** Do not confuse ~~CT alone~~ with the correct answer. For nodules 10–20 mm with low AFP, **two imaging modalities are required** — CT + MRI is the standard combination.